Sercan Aksoy
About
In The Last Decade
Sercan Aksoy
254 papers receiving 3.5k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 1.7k
- Pulmonary and Respiratory Medicine 780
- Molecular Biology 554
- Cancer Research 430
- Surgery 428
Countries citing papers authored by Sercan Aksoy
This map shows the geographic impact of Sercan Aksoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sercan Aksoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sercan Aksoy more than expected).
Fields of papers citing papers by Sercan Aksoy
This network shows the impact of papers produced by Sercan Aksoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sercan Aksoy. The network helps show where Sercan Aksoy may publish in the future.
Co-authorship network of co-authors of Sercan Aksoy
This figure shows the co-authorship network connecting the top 25 collaborators of Sercan Aksoy. A scholar is included among the top collaborators of Sercan Aksoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sercan Aksoy. Sercan Aksoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 1 | |
| 5 | 7 | |
| 6 | 6 | |
| 7 | 1 | |
| 8 | 9 | |
| 9 | 5 | |
| 10 | Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data. | 2 |
| 11 | 22 | |
| 12 | 9 | |
| 13 | 5 | |
| 14 | 0 | |
| 15 | Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey. | 3 |
| 16 | Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer. | 9 |
| 17 | Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. | 7 |
| 18 | Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer. | 5 |
| 19 | Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients. | 3 |
| 20 | Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.